Guidelines for diagnosis and treatment of glucocorticoid-induced osteoporosis.
10.3760/cma.j.cn112138-20221025-00787
- Author:
Jing HE
1
;
Fen LI
2
;
Wen Hui HUANG
3
;
Li Ping WANG
4
;
Xue Wu ZHANG
1
;
Yan ZHAO
5
Author Information
1. Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
2. Department of Rheumatology and Immunology, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
3. Department of Rheumatology and Immunology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
4. Department of Rheumatology, Lanzhou University Second Hospital, Lanzhou 730030, China.
5. Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Glucocorticoids/adverse effects*;
Quality of Life;
Osteoporosis/therapy*;
Incidence;
Rheumatology;
Bone Density
- From:
Chinese Journal of Internal Medicine
2023;62(6):631-638
- CountryChina
- Language:Chinese
-
Abstract:
Glucocorticoid-induced osteoporosis (GIOP) is a skeletal disease characterized by decreased bone strength and increased fracture risk associated with long-term glucocorticoid use. GIOP is the most common secondary osteoporosis that critically affects the quality of life of patients. Currently, the incidence of GIOP in China remains high, with insufficient awareness and lack of prevention and treatment norms. Therefore, the Chinese Rheumatology Association has established this standard based on domestic and international experience, with the aim of raising awareness of prevention and treatment among clinicians, guiding the standardized diagnosis and treatment of this disease, and improving the overall prognosis of patients with GIOP.
